Dr Kevin Bilyard
Managing Partner (UK)
Kevin has extensive experience of new product development and growing businesses. He started with Smith Kline & French (now GSK) and then ICI Pharmaceuticals (now AZ) working in research, product development and strategic marketing.
In 1997 he joined Quadrant Healthcare as Product Development Director and was part of the management team that led the company’s IPO on the London Stock Exchange in 1998.
He gained experience in M&A transactions and formation of joint ventures and, when Quadrant was acquired by Elan in 2000, he established Development and Management Resources, an independent business providing advisory services which later became Nine-TZ Healthcare Ventures.
He has held executive and advisory roles, including board level positions, with several emerging biotech companies and became CEO of Immodulon Therapeutics, an immuno-oncology company, soon after its formation in 2007.
He graduated with first class honors in Medicinal Chemistry from University College London where he also completed research leading to his PhD.